𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients

✍ Scribed by Mathias Warm; Ronald Kates; Friedrich Overkamp; Anke Thomas; Nadia Harbeck

Publisher
Springer US
Year
2010
Tongue
English
Weight
238 KB
Volume
125
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Early treatment benefits of ropinirole p
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
✍ Bonnie P. Hersh; Nancy L. Earl; Robert A. Hauser; Mark Stacy πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 488 KB πŸ‘ 1 views

A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn

Fulvestrant versus anastrozole for the t
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women : A prospective combined analysis of two multicenter trials
✍ John F. R. Robertson; C. Kent Osborne; Anthony Howell; Stephen E. Jones; Louis M πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 119 KB

## Abstract ## BACKGROUND Fulvestrant (ICI 182,780) is a new type of estrogen receptor (ER) antagonist that down‐regulates the ER and has no known agonist effects. The authors report the prospectively planned combined analysis of data from 2 Phase III trials comparing fulvestrant 250 mg monthly (_